Anti-Human Siglec-2/CD22 Polyclonal Antibody (HB011014)

Name: Anti-Human Siglec-2/CD22 Polyclonal Antibody
Brand: abinScience
SKU: HB011014
Price: 168 USD
Availability: InStock

데이터시트 제품 공유 정보 복사

가격(USD):

사양:

50ug
100ug

수량:

문의하기

개요
이미지
참고 문헌
데이터시트
SDS

개요

카탈로그 번호

HB011014

설명

Anti-CD22 Polyclonal Antibody (HB011014) is a rabbit polyclonal antibody detecting CD22 in ELISA, IHC, WB. Suitable for Human, Pan paniscus, Pan troglodytes, and Pongo pygmaeus.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.
●Multi-Species — Cross-reactive for translational research.

종 반응성

Human

응용 분야

ELISA, IHC, WB

숙주 종

Rabbit

클론성

Polyclonal

이소타입

IgG

면역원

E. coli - derived recombinant Human CD22 (Trp176-Ala330).

타겟

B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, CD22, SIGLEC2, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14

내독소 수준

Please contact with the lab for this information.

순도

>90% as determined by SDS-PAGE.

정제

Purified by antigen affinity column.

등록번호

P20273

형태

Liquid

저장 완충액

0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300.

데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.

제품 사용 정보

응용 분야	희석
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

안정성 및 저장

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

배경

B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa).

1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755

2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166

3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905

4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366

참고사항

For research use only.

이미지

참고 문헌

데이터시트